Get the Stockscreener App
2.46
1.20%
-0.03
After Hours:
2.35
-0.11
-4.47%
Equillium Inc stock is traded at $2.46, with a volume of 278.63K.
It is down -1.20% in the last 24 hours and down -19.34% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$2.49
Open:
$2.51
24h Volume:
278.63K
Relative Volume:
0.37
Market Cap:
$155.54M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-4.8254
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
-0.40%
1M Performance:
-19.34%
6M Performance:
+89.23%
1Y Performance:
+510.88%
1-Day Range:
$2.45
$2.65
1-Week Range:
$2.45
$2.86
52-Week Range:
$0.37
$3.54
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.46 | 157.43M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Equillium Inc (EQ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Equillium Inc (EQ) Cash Flow - TradingKey
EQ|Equillium Inc|Price:2.490|Chg%:-0.200 - TradingKey
EQ|Equillium Inc|Price:2.580|Chg%:+0.090 - TradingKey
TradingKey - TradingKey
Equillium Inc (EQ) Balance Sheet - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Equillium (EQ), CSL (CMXHF) - The Globe and Mail
Equillium Inc (EQ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clear Street Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Equillium: The Market Seems To Have Already Priced In Phase 1 Success (NASDAQ:EQ) - Seeking Alpha
Clear Street Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $9 - Moomoo
Clear Street initiates Equillium stock with buy rating on IBD drug potential - Investing.com Nigeria
Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20 - Moomoo
Equillium Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Revision Downgrade - dars.gov.et
EQUILLIUM INC : PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $20 - webull.com
Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target - marketscreener.com
EQ Initiated Coverage by Piper SandlerRating Set to Overweigh - GuruFocus
Piper Sandler initiates Equillium stock with overweight rating - Investing.com
ETFs Investing in Equillium, Inc. Stocks - TradingView
EQ Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Development CostsSaaS Earnings Trends - dars.gov.et
EQ Q1 2026 Earnings: EPS Misses Estimates as Company Continues Development-Stage OperationsEarnings Risk Report - dars.gov.et
Equillium(EQ) Stock Options Chain | Quotes & News - Moomoo
EQ News | EQUILLIUM INC (NASDAQ:EQ) - ChartMill
Equillium (EQ) Gets a Buy from Oppenheimer - The Globe and Mail
Equillium (EQ) Cantor Global Healthcare Conference 2025 Summary - Quartr
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
EQ Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Focuses on Pipeline ProgressPre-Earnings Setup - dars.gov.et
Equillium stock rating reaffirmed by Oppenheimer on rival drug data - Investing.com Canada
Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Growth Benchmark - marketscreener.com
Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Index - marketscreener.com
Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Index - marketscreener.com
Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Equillium Inc. (EQ) Q1 2026 Earnings: EPS Misses Estimates, Stock Gains 3.39% Amid Strategic Progress - dars.gov.et
Price to book forward of Equillium, Inc. – NASDAQ:EQ - TradingView
Enterprise value to EBIT forward of Equillium, Inc. – NASDAQ:EQ - TradingView
Price to sales forward of Equillium, Inc. – NASDAQ:EQ - TradingView
Price to earnings forward of Equillium, Inc. – NASDAQ:EQ - TradingView
Equillium, Inc. Actuals & Estimates (NASDAQ:EQ) - TradingView
EQ Forecast — Price Target — Prediction for 2027 - TradingView
EQ Q1 2026 Earnings: EPS Miss Amid Pipeline Progress; Stock Rises 3%Special Dividend Alert - dars.gov.et
Equillium Inc (EQ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
EQ Q1 2026 Earnings: EPS Miss Reflects Higher R&D Spend; Stock Gains SlightlyEarnings Revision Upgrade - dars.gov.et
EQUILLIUM INC (EQ) Stock Chart - ChartMill
23% Of This Equillium Insider's Holdings Were Sold - simplywall.st
Equillium Inc (EQ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Equillium Inc (EQ) Institutional Confidence - TradingKey
Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Equillium Inc (EQ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Equillium Inc (EQ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Equillium Inc (EQ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Equillium Inc. (EQ) Jumps 8.7%: Volume Surge and Key Resistance AheadCall Resistance - dars.gov.et
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):